Isolated limb perfusion for melanoma in-transit metastases: Developments in recent years and the role of tumor necrosis factor alpha

Current Opinion in Oncology

Volumn 23, Issue 2, 2011, Pages 183-188

  Deroose, Jan P ^a   Eggermont, Alexander M M ^a   Van Geel, Albertus N ^a   Verhoef, Cornelis ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

in transit metastases; isolated limb perfusion; melanoma; tumor necrosis factor

Indexed keywords

B RAF KINASE INHIBITOR; BCG VACCINE; CARBOPLATIN; DACARBAZINE; DACTINOMYCIN; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RADIOTHERAPY; CARBON DIOXIDE LASER; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HYPERTHERMIC THERAPY; IN-TRANSIT METASTASIS; ISOLATED LIMB PERFUSION; LIMB PERFUSION; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HUMANS; MELANOMA; MELPHALAN; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952007770     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283424dbc     Document Type: Article

References (76)

1. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer statistics review. Bethesda, MD: National Cancer Institute; based on November 2009 SEER data submission, posted to the SEER website; 2010. Vol. 2010, pp. 1975-2007.
2. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666-1674.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
4. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996; 26:335-349. (Pubitemid 126734884)
5. Pawlik TM, Ross MI, Thompson JF, et al. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005; 23:4588-4590.
6. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994; 115:39-45. (Pubitemid 24039210)
7. Lingam MK, Byrne DS, Aitchison T, et al. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer 1996; 32A:1668-1673.
8. Aloia TA, Grubbs E, Onaitis M, et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 2005; 140:1115-1120. (Pubitemid 41668683)
9. Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995; 19:363-368.
10. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997; 132:903-907. (Pubitemid 27344144)
11. Di Filippo F, Anza M, Rossi CR, et al. The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 1998; 14:215-223. (Pubitemid 28146513)
12. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139:1237-1242. (Pubitemid 39463461)
13. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006; 24:4196-4201. (Pubitemid 46622299)
14. Alexander HR Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28:114-118.
15. Rossi CR, Pasquali S, Mocellin S, et al. Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol 2010; 17:3000-3007.
16. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
17. Lejeune FJ, Lienard D, Leyvraz S, Mirimanoff RO. Regional therapy of melanoma. Eur J Cancer 1993; 29A:606-612. (Pubitemid 23036318)
18. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994; 73:483-492. (Pubitemid 24030632)
19. Eggermont AM, Lienard D, Schraffordt Koop H. High dose tumor necrosis factor-alpha in isolated perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat 1995; 7:32-36.
20. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491-502. (Pubitemid 29494115)
21. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004; 11:173-177. (Pubitemid 40486792)
22. Grunhagen DJ, Brunstein F, Graveland WJ, et al. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004; 240:939-947; discussion 947-948.
23. Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and softtissue sarcoma. Ann Surg Oncol 2007; 14:230-238. (Pubitemid 44954294)
24. Di Filippo F, Giacomini P, Rossi CR, et al. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo 2009; 23:347-352.
25. Lasithiotakis K, Economou G, Gogas H, et al. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multiinstitutional Hellenic collaborative study. Oncol Rep 2010; 23:1077-1083.
26. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008; 15:1476-1484.
27. Ebskov LB. Major amputation for malignant melanoma: an epidemiological study. J Surg Oncol 1993; 52:89-91. (Pubitemid 23061955)
28. Gibson SC, Byrne DS, McKay AJ. Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg 2004; 91:893-895. (Pubitemid 38901357)
29. Kandamany N, Mahaffey P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci 2009; 24:411-414.
30. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19:985-990.
31. Garbe C. Perspectives of cytokine treatment in malignant skin tumors. Recent Results Cancer Res 1995; 139:349-369.
32. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin .2. therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116. (Pubitemid 29318842)
33. Hauschild A, Weichenthal M, Balda BR, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21:2883-2888. (Pubitemid 46621837)
34. Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15:45-51. (Pubitemid 40354473)
35. Sersa G, Miklavcic D, Cemazar M, et al. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34:232-240.
36. Testori A, Rutkowski P, Marsden J, et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6):vi22-vi29.
37. Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 2007; 110:1791-1795. (Pubitemid 47557304)
38. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 2009; 25:323-334.
39. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-1836. (Pubitemid 39036756)
40. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010; 21 (Suppl 7):vii339-vii344.
41. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
42. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
43. Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148: 616-632.
44. Klaase JM, Kroon BB, van Geel AN, et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993; 80:1124-1126. (Pubitemid 23284036)
45. Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988; 14:157-163.
46. Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992; 16:227-233.
47. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18:905-910. (Pubitemid 13147887)
48. Omlor G. Optimization of isolated hyperthermic limb perfusion. World J Surg 1993; 17:134.
49. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967; 20:1351-1381.
50. Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994; 4:365-370. (Pubitemid 24381889)
51. Vrouenraets BC, Klaase JM, Kroon BB, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995; 130:43-47.
52. Boesch CE, Meyer T, Waschke L, et al. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Int J Hyperthermia 2010; 26:16-20.
53. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14:238-247. (Pubitemid 28146516)
54. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9:127-136. (Pubitemid 34259697)
55. Beasley GM, Caudle A, Petersen RP, et al. A multiinstitutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009; 208:706-715; discussion 715-717.
56. Barbour AP, Thomas J, Suffolk J, et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 2009; 16:3463-3472.
57. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009; 16:1184-1192.
58. Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, theWorld Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998; 16:2906-2912. (Pubitemid 28417408)
59. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol 1991; 9:2091-2094.
60. Klaase JM, Kroon BB, van Geel AN, et al. A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71:2990-2994. (Pubitemid 23145528)
61. Lindner P, Thompson JF, De Wilt JH, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004; 30:433-439. (Pubitemid 38528929)
62. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer 2009; 115:1932-1940.
63. Sugarman BJ, Aggarwal BB, Hass PE, et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1985; 230:943-945. (Pubitemid 16193990)
64. Yamauchi N, Watanabe N, Maeda M, et al. Mechanism of synergistic cytotoxic effect between tumor necrosis factor and hyperthermia. Jpn J Cancer Res 1992; 83:540-545.
65. De Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000; 82:1000-1003. (Pubitemid 30128849)
66. Van der Veen AH, de Wilt JH, Eggermont AM, et al. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances antitumour effects. Br J Cancer 2000; 82:973-980. (Pubitemid 30085254)
67. De Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80:161-166. (Pubitemid 29210102)
68. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996; 14:479-489.
69. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996; 83:1319-1328. (Pubitemid 26342147)
70. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferongamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665. (Pubitemid 26329649)
71. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in .186. patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756- 764; discussion 764-765.
72. Lejeune FJ, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007; 25:1449-1450; author reply 1450-1451. (Pubitemid 46706902)
73. Grunhagen DJ, de Wilt JH, van Geel AN, et al. TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 2005; 31:1011-1019. (Pubitemid 41671116)
74. Stam TC, Swaak AJ, de Vries MR, et al. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000; 7:268-275. (Pubitemid 30318314)
75. Van Etten B, van Geel AN, de Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003; 10:32-37.
76. Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001; 27:390-395. (Pubitemid 32624542)